Athersys Reports Alignment of Key Regulators for Pivotal Registration Study in Stroke
August 07, 2017 06:00 ET
|
Athersys, Inc.
MultiStem® stem cell technology receives Positive Opinion from European Medicines Agency Adds to Special Protocol Assessment and Fast Track designation in U.S., and Priority Review under Sakigake...
Athersys Announces Acceptance by PMDA of Clinical Trial Notification in Japan for Treatment of Ischemic Stroke With MultiStem®
September 12, 2016 06:30 ET
|
Athersys, Inc.
CLEVELAND, Sept. 12, 2016 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) announced today the successful completion of Japan’s Pharmaceutical and Medical Devices Agency (PMDA) review of the...